drugset

drugset / Trial / NCT07048197

A Study to Assess Safety, Cellular Kinetics and Exploratory Efficacy of Rapcabtagene Autoleucel in Rheumatoid Arthritis and Sjogren's Disease

NCT07048197 ↗

Phase 1/2 Recruiting 27 enrolled Novartis Pharmaceuticals

Non-randomizedParallel-groupOpen-labelTreatment

Summary

A study to assess safety, cellular kinetics and exploratory efficacy of rapcabtagene autoleucel in rheumatoid arthritis and Sjogren's disease

Timeline

Start: 2025-06-20
Primary completion: 2028-11-01
Completion: 2028-11-01

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	rapcabtagene autoleucel	Cell therapy	—	—

Indications